Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Du, Yan ^a   Su, Tong ^a   Zhao, Lijun ^b   Tan, Xiaojie ^a   Chang, Wenjun ^a   Zhang, Hongwei ^a   Cao, Guangwen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DNA REPAIR GENE; DRUG RESPONSE; EXCISION REPAIR; EXCISION REPAIR CROSS COMPLEMENTATION GROUP 1 GENE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIPLE DRUG RESISTANCE 1 GENE; ONCOGENE; OVERALL SURVIVAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; X RAY REPAIR CROSS COMPLEMENTING GROUP 1 GENE; X RAY REPAIR CROSS COMPLEMENTING GROUP 3 GENE; XERODERMA PIGMENTOSUM GROUP D GENE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DEMOGRAPHY; DNA REPAIR; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; SURVIVAL;

ABCB1 PROTEIN, HUMAN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DEMOGRAPHY; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS;

EID: 84903127246     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099843     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Wu L, Chang W, Zhao J, Yu Y, Tan X, et al. (2010) Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res 16: 3760-3768.
3. Sekine I, Yamamoto N, Nishio K, Saijo N (2008) Emerging ethnic differences in lung cancer therapy. Br J Cancer 99: 1757-1762.
4. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
5. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, et al. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360. (Pubitemid 38101630)
6. Yoo SS, Choi JE, Lee WK, Choi YY, Kam S, et al. (2009) Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. J Clin Oncol 27: 5823-5829.
7. Park JY, Lee WK, Jung DK, Choi JE, Park TI, et al. (2009) Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clin Cancer Res 15: 1794-1800.
8. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, et al. (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991. (Pubitemid 44343542)
9. Wei Q, Frazier ML, Levin B (2000) DNA repair: a double-edged sword. J Natl Cancer Inst 92: 440-441. (Pubitemid 30182874)
10. Rosell R, Lord RV, Taron M, Reguart N (2002) DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227. (Pubitemid 35341796)
11. Tanaka Y, Maniwa Y, Bermudez VP, Doi T, Nishio W, et al. (2010) Nonsynonymous single nucleotide polymorphisms in DNA damage repair pathways and lung cancer risk. Cancer 116: 896-902.
12. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2006) Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 27: 560-567. (Pubitemid 43372885)
13. Zhang X, Miao X, Liang G, Hao B, Wang Y, et al. (2005) Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 65: 722-726. (Pubitemid 40216429)
14. Wolfe KJ, Wickliffe JK, Hill CE, Paolini M, Ammenheuser MM, et al. (2007) Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression. Pharmacogenet Genomics 17: 897-905. (Pubitemid 350293790)
15. Hao B, Wang H, Zhou K, Li Y, Chen X, et al. (2004) Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 64: 4378-4384. (Pubitemid 38802447)
16. Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, et al. (2011) Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: A prospective clinical study. Cancer.
17. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, et al. (2010) Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28: 4945-4952.
18. Kim HT, Lee JE, Shin ES, Yoo YK, Cho JH, et al. (2008) Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 26: 5972-5979.
19. Kim M, Kang HG, Lee SY, Lee HC, Lee EB, et al. (2010) Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. Cancer Sci 101: 2436-2442.
20. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478. (Pubitemid 30183327)
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
22. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, et al. (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803. (Pubitemid 351469466)
23. Yarden RI, Papa MZ (2006) BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Mol Cancer Ther 5: 1396-1404. (Pubitemid 44070475)
24. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, et al. (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63: 6221-6228. (Pubitemid 37255167)
25. Lafarge S, Sylvain V, Ferrara M, Bignon YJ (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20: 6597-6606. (Pubitemid 32980286)
26. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, et al. (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13: 2443-2449. (Pubitemid 39377848)
27. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, et al. (2007) BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2: e1129.
28. Bonanno L, Costa C, Majem M, Favaretto A, Rugge M, et al. (2013) The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Ann Oncol 24: 1130-1132.
29. Yang Y, Xie Y, Xian L (2013) Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysis. J Exp Clin Cancer Res 32: 15.
30. Lee KM, Nizza S, Hayes T, Bass KL, Irmisch A, et al. (2007) Brc1-mediated rescue of Smc5/6 deficiency: requirement for multiple nucleases and a novel Rad18 function. Genetics 175: 1585-1595. (Pubitemid 46789946)
31. Chang JS, Yeh RF, Wiencke JK, Wiemels JL, Smirnov I, et al. (2008) Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Biomarkers Prev 17: 1368-1373.
32. He J, Xu Y, Qiu LX, Li J, Zhou XY, et al. (2012) Polymorphisms in ERCC1 and XPF genes and risk of gastric cancer in an eastern Chinese population. PLoS One, 7:e49308.
33. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, et al. (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291. (Pubitemid 34753602)
34. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, et al. (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25: 2747-2754. (Pubitemid 47123183)
35. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, et al. (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16: 555-560.
36. Isla D, Sarries C, Rosell R, Alonso G, Domine M, et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-smallcell lung cancer. Ann Oncol 15: 1194-1203. (Pubitemid 39199306)
37. Dong J, Hu Z, Shu Y, Pan S, Chen W, et al. (2012) Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis. Mol Carcinog 51: 546-552.
38. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, et al. (2010) Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67: 101-107.
39. Wei HB, Lu XS, Shang LH, Xu G, Hu J, et al. (2011) Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinumbased chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res 42: 412-420.
40. Hubner RA, Riley RD, Billingham LJ, Popat S (2011) Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a metaanalysis of published studies and recommendations. PLoS One 6:e25164.
41. Campa D, Sainz J, Pardini B, Vodickova L, Naccarati A, et al. (2012) A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. PLoS One 7: e32784.
42. Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, et al. (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71: 191-198.
43. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ (2012) Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One 7:e38150.
44. Albino AP, Jorgensen ED, Rainey P, Gillman G, Clark TJ, et al. (2009) gammaH2AX: A potential DNA damage response biomarker for assessing toxicological risk of tobacco products. Mutat Res 678: 43-52.